Stock Events

Stock Events

Zealand Pharma A/S. 

€38.68
0
+€0.46+1.2% Today

Statistics

Day High
38.92
Day Low
37.23
52W High
73.9
52W Low
31.24
Volume
0
Avg. Volume
176
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

7MayExpected
Q4 2025
Next
-1.18
-1.05
-0.92
-0.79
Expected EPS
-1.181007093943344
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow 22Z.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Novo Nordisk
NVO
Mkt Cap167.44B
Novo Nordisk is a leading global healthcare company that competes with Zealand Pharma in the diabetes and obesity drug markets, areas where Zealand Pharma also operates.
Sanofi
SNY
Mkt Cap113.88B
Sanofi is a large pharmaceutical company that competes with Zealand Pharma in the development of treatments for diabetes and cardiovascular diseases.
Lilly(Eli) &
LLY
Mkt Cap840.84B
Eli Lilly is a major player in the pharmaceutical industry, competing with Zealand Pharma in the diabetes care sector, particularly in the development of GLP-1 receptor agonists.
Astrazeneca
AZN
Mkt Cap316.3B
AstraZeneca competes with Zealand Pharma in several areas, including the development of new treatments for diabetes and other metabolic disorders.
Merck
MRK
Mkt Cap300.2B
Merck is a global healthcare company that competes with Zealand Pharma in the diabetes sector, particularly in the development of novel therapeutics.
Medicinova
MNOV
Mkt Cap69.4M
MediciNova is involved in the development of novel therapeutics for diseases with unmet medical needs, overlapping with Zealand Pharma's focus areas.
Novartis
NVS
Mkt Cap297.35B
Novartis is a global healthcare company that has a broad range of products competing in the diabetes and cardiovascular markets, overlapping with Zealand Pharma's focus areas.
Bristol-Myers Squibb
BMY
Mkt Cap119.69B
Bristol-Myers Squibb operates in multiple therapeutic areas including cardiovascular diseases, directly competing with some of Zealand Pharma's therapeutic development areas.
Regeneron Pharmaceuticals
REGN
Mkt Cap79.17B
Regeneron Pharmaceuticals competes with Zealand Pharma in the development of treatments for cardiovascular diseases, among other areas.
Vertex Pharmaceuticals
VRTX
Mkt Cap110.97B
Vertex Pharmaceuticals is involved in creating transformative medicines for people with serious diseases, competing with Zealand Pharma's innovative approach to drug development.

About

Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark and the United States. The company has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. It also provides Zegalogue, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon. Its pipeline includes Dasiglucagon for treating congenital hyperinsulinism. In addition, the company developing glepaglutide, a long acting GLP-2 analog, which is in Phase III clinical trials for the treatment of short bowel syndrome. The company was incorporated in 1997 and is based in Søborg, Denmark.
Show more...
CEO
Mr. Adam Sinding Steensberg M.D.
Employees
481
Country
Denmark
ISIN
DK0060257814

Listings

OTC Link
US
ZLDPY
F
DE
22Z1.F
STU
DE
22Z.STU
CO
DK
ZEAL.CO

0 Comments

Share your thoughts

FAQ

What is Zealand Pharma A/S. stock price today?▼
The current price of 22Z.STU is €38.68 EUR — it has increased by +1.2% in the past 24 hours. Watch Zealand Pharma A/S. stock price performance more closely on the chart.
What is Zealand Pharma A/S. stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Zealand Pharma A/S. stocks are traded under the ticker 22Z.STU.
Is Zealand Pharma A/S. stock price growing?▼
22Z.STU stock has fallen by -6.28% compared to the previous week, the month change is a +8.42% rise, over the last year Zealand Pharma A/S. has showed a -34.23% decrease.
When is the next Zealand Pharma A/S. earnings date?▼
Zealand Pharma A/S. is going to release the next earnings report on May 07, 2026.
What were Zealand Pharma A/S. earnings last quarter?▼
22Z.STU earnings for the last quarter are -0.79 EUR per share, whereas the estimation was -1.07 EUR resulting in a +26.16% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Zealand Pharma A/S. have?▼
As of April 13, 2026, the company has 481 employees.
In which sector is Zealand Pharma A/S. located?▼
Zealand Pharma A/S. operates in the Health & Wellness sector.
When did Zealand Pharma A/S. complete a stock split?▼
Zealand Pharma A/S. has not had any recent stock splits.
Where is Zealand Pharma A/S. headquartered?▼
Zealand Pharma A/S. is headquartered in Søborg, Denmark.